Share this post on:

product name Genistein


Description: Genistein, a phytoestrogen found in soy products, is a highly specific inhibitor of protein tyrosine kinase (PTK) which blocks the mitogenic effect mediated by EGF on NIH-3T3 cells with IC50 of 12 μM or by insulin with IC50 of 19 μM. Genistein has a wide range of biological actions, it inhibits protein tyrosine kinases including epidermal growth factor receptor kinase. Also binds to PPARγ and estrogen receptors and acts as an agonist at GPR30. Also available as part of the MAP.

References: J Biol Chem. 1987 Apr 25;262(12):5592-5; J Nutr. 2002 Mar;132(3):552S-558S.



Molecular Weight (MW)

270.24
Formula

C15H10O5
CAS No.

446-72-0
Storage

-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)

DMSO: 54 mg/mL (199.8 mM)
Water: <1 mg/mL
Ethanol: 2 mg/mL (7.4 mM)
Solubility (In vivo)

 
Synonyms

 

other peoduct :References PubMed ID::http://www.ncbi.nlm.nih.gov/pubmed/19417104

In Vitro

In vitro activity: Genistein is an ATP competitive inhibitor. Genistein inhibits tyrosine phosphorylation in isolated enzyme and receptor preparations and in whole cells including platelets, lymphocytes and a variety of cultured cells. It also inhibits EGF-stimulated phosphorylation in cultured cells as well as inhibition of Topo II (topoisomerase II). Genistein inhibits EGF-stimulated tyrosine phosphorylation in cultured A431 epidermoid carcinoma cells. Inhibition is competitive with ATP and noncompetitive with substrate. Genistein blocks the mitogenic effect mediated by EGF, insulin and thrombin on NIH-3T3 cells. Genistein also acts as an agonist at the GPR30 receptor and binds to PPARγ and estrogen receptors. Genistein also binds to PPARγ, acting as an agonist at this receptor with Ki of 5.7 μM.


Kinase Assay:


Cell Assay:  

In Vivo Genistein has chemopreventive effects on breast, prostate, and other endocrine-dependent tumors in adult animals. Genistein in the diet reduced the incidence of poorly differentiated prostatic adenocarcinomas in a dose-dependent manner and down-regulated androgen receptor, estrogen receptor-alpha, progesterone receptor, epidermal growth factor receptor, insulin-like growth factor-I, and extracellular signal-regulated kinase-1 but not estrogen receptor-beta and transforming growth factor-alpha mRNA expressions. Dietary genistein protects against mammary and prostate cancers by regulating specific sex steroid receptors and growth factor signaling pathways. Genistein combined with prostate tumor irradiation causes greater inhibition of primary tumor growth and increases control of spontaneous metastasis to para-aortic lymph nodes, increasing mouse survival. Paradoxically, treatment with genistein alone increases metastasis to lymph nodes.
Animal model  
Formulation & Dosage  
References  

THZ3

Share this post on:

Author: Sodium channel